ArticleBMC cancer2006
Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer.
Article in BMC cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- FKBPL: a marker of good prognosis in breast cancer.Oncotarget · 2015Pooled it
- 6q deletion is frequent but unrelated to patient prognosis in breast cancer.Breast cancer (Tokyo, Japan) · 2022Article
- Applications of Topological Data Analysis in Oncology.Frontiers in artificial intelligence · 2021Review
- SALMON: Survival Analysis Learning With Multi-Omics Neural Networks on Breast Cancer.Frontiers in genetics · 2019Article
- Identification of polymorphisms in cancer patients that differentially affect survival with age.Aging · 2017Article
- Identification of Copy Number Aberrations in Breast Cancer Subtypes Using Persistence Topology.Microarrays (Basel, Switzerland) · 2015Article
- CDK11p58 inhibits ERα-positive breast cancer invasion by targeting integrin β3 via the repression of ERα signaling.BMC cancer · 2014Article
- Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer.Cancer cell · 2013Article
- Germline and somatic KLLN alterations in breast cancer dysregulate G2 arrest.Human molecular genetics · 2013Article
- Estrogenic regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation.Oncogene · 2012Article
- The role of S6K1 in ER-positive breast cancer.Cell cycle (Georgetown, Tex.) · 2012Article
- Challenges in identifying candidate amplification targets in human cancers: chromosome 8q21 as a case study.Genes & cancer · 2012Article
- Article
- 17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy.Experimental and therapeutic medicine · 2011Article
- Identification of metastasis-associated breast cancer genes using a high-resolution whole genome profiling approach.Journal of cancer research and clinical oncology · 2011Article
- Chemo-resistant protein expression pattern of glioblastoma cells (A172) to perillyl alcohol.Journal of proteome research · 2011Article
- Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma.Hepatology (Baltimore, Md.) · 2010Article
- Article
- Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA considerable proportion of estrogen receptor (ER)-positive breast cancer recurs despite tamoxifen treatment, which is a serious problem commonly encountered in clinical practice. We tried to find novel prognostic markers in this subtype of breast cancer.
methodsWe performed array comparative genomic hybridization (CGH) with 1,440 human bacterial artificial chromosome (BAC) clones to assess copy number changes in 28 fresh-frozen ER-positive breast cancer tissues. All of the patients included had received at least 1 year of tamoxifen treatment. Nine patients had distant recurrence within 5 years (Recurrence group) of diagnosis and 19 patients were alive without disease at least 5 years after diagnosis (Non-recurrence group).
resultsPotential prognostic variables were comparable between the two groups. In an unsupervised clustering analysis, samples from each group were well separated. The most common regions of gain in all samples were 1q32.1, 17q23.3, 8q24.11, 17q12-q21.1, and 8p11.21, and the most common regions of loss were 6q14.1-q16.3, 11q21-q24.3, and 13q13.2-q14.3, as called by CGH-Explorer software. The average frequency of copy number changes was similar between the two groups. The most significant chromosomal alterations found more often in the Recurrence group using two different statistical methods were loss of 11p15.5-p15.4, 1p36.33, 11q13.1, and 11p11.2 (adjusted p values < 0.001). In subgroup analysis according to lymph node status, loss of 11p15 and 1p36 were found more often in Recurrence group with borderline significance within the lymph node positive patients (adjusted p = 0.052).
conclusionOur array CGH analysis with BAC clones could detect various genomic alterations in ER-positive breast cancers, and Recurrence group samples showed a significantly different pattern of DNA copy number changes than did Non-recurrence group samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.